Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 2

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Jan 14, 2025; 31(2): 101292
Published online Jan 14, 2025. doi: 10.3748/wjg.v31.i2.101292

Full Size Figure Download Figure

Figure 1 Study enrollment process. TGN: Thioguanine nucleotides.

Citation: Chaemsupaphan T, Pudipeddi A, Lin HY, Paramsothy S, Kariyawasam VC, Kermeen M, Leong RW. Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study. World J Gastroenterol 2025; 31(2): 101292
URL: https://www.wjgnet.com/1007-9327/full/v31/i2/101292.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i2.101292

Chaemsupaphan T, Pudipeddi A, Lin HY, Paramsothy S, Kariyawasam VC, Kermeen M, Leong RW. Vedolizumab serum trough concentrations with and without thiopurines in ulcerative colitis: The prospective VIEWS pharmacokinetics study. World J Gastroenterol 2025; 31(2): 101292 [PMID: 39811508 DOI: 10.3748/wjg.v31.i2.101292]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.